Celltrion’s Rituximab Biosimilar Enjoys A Market Share Of More Than A Third In Europe

Within 18 months of hitting European markets, Celltrion’s rituximab biosimilar of Roche’s MabThera/Rituxan oncology and autoimmune diseases brand has captured a share of more than a third; meanwhile the Korean firm has updates for its trastuzumab and infliximab biosimilar medicines.